Abcam, ab251511, Anti-AKR1C3+AKR1C4 antibody [EPR16726] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal AKR1C3 antibody. Carrier free. Suitable for ICC/IF, IP, WB, Flow Cyt (Intra) and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR16726,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:ICC/IF, IP, Flow Cyt (Intra), WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab251511 is the carrier-free version of
ab209899
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The proteins AKR1C3 and AKR1C4 also known as Aldo-Keto Reductase Family 1 Member C3 and C4 are reductases involved in the metabolism of steroids prostaglandins and xenobiotics. AKR1C3 has a molecular mass of approximately 37 kDa while AKR1C4 is slightly larger at around 37.2 kDa. These proteins are expressed mainly in the liver but you can also find AKR1C3 in adrenal glands and prostate tissues. Current research shows their functions in enzymatic reduction processes significantly affect hormone conversion and lipid metabolism.
Biological function summary
The proteins AKR1C3 and AKR1C4 have significant roles in steroid hormone metabolism. They do not form a part of any larger complex but act independently to catalyze the conversion of active androgens and estrogens. AKR1C3 for example converts androstenedione to testosterone and estrone to estradiol affecting steroid balance in tissues. Meanwhile AKR1C4 primarily catalyzes the reduction of bile acid intermediates assisting in maintaining liver health and function.
Pathways
AKR1C3 and AKR1C4 operate closely in metabolic pathways involving steroid metabolism and bile acid biosynthesis. In the steroid metabolism pathway they associate with other enzymes like 5α-reductase and CYP19A1 (aromatase) to regulate the conversion and amplification of steroid hormones. In bile acid biosynthesis AKR1C4 works conjointly with enzymes like CYP7A1 playing a significant role in processing cholesterol substrates into bile acids important for lipid digestion and absorption.
AKR1C3 and AKR1C4 have associations with conditions such as prostate cancer and liver disease. AKR1C3's upregulation correlates with prostate cancer progression by influencing androgen receptor activation. It relates to enzymes like CYP17A1 which share involvement in androgen biosynthesis. Meanwhile AKR1C4 plays a role in liver diseases such as cholestasis and is thought to interact with proteins involved in bile transport and synthesis potentially impacting pathological bile acid accumulation. Understanding these interactions helps inform therapeutic strategies targeting hormone and bile acid-related disorders.